WEKO3
アイテム
肝細胞癌におけるレンバチニブ投与後の血圧上昇は良好な予後のサロゲートマーカーになり得る
http://hdl.handle.net/10232/0002001250
http://hdl.handle.net/10232/0002001250fc5bc8f5-85cc-4f51-a035-0049e7d8d098
.png)
| Item type | 学位論文 / Thesis or Dissertation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2025-07-07 | |||||
| タイトル | ||||||
| タイトル | Blood Pressure Elevations Post-Lenvatinib Treatment in Hepatocellular Carcinoma: A Potential Marker for Better Prognosis | |||||
| タイトル言語 | en | |||||
| タイトル | ||||||
| タイトル | 肝細胞癌におけるレンバチニブ投与後の血圧上昇は良好な予後のサロゲートマーカーになり得る | |||||
| タイトル言語 | ja | |||||
| 著者 |
柴田, 啓佑
× 柴田, 啓佑 |
|||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Lenvatinib | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Onco-Hypertension | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | VEGF Inhibitors | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||
| 資源タイプ | doctoral thesis | |||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| 要約 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Lenvatinib is a tyrosine kinase inhibitor that effectively inhibits vascular endothelial growth factor signaling and is used for treating hepatocellular carcinoma. However, angiogenesis inhibitors often cause hypertension. Although lenvatinib-induced hypertension has been proposed as a potential surrogate marker for better prognosis, studies on blood pressure elevations and outcomes following lenvatinib initiation are limited. This study included 67 patients who underwent lenvatinib therapy at the Department of Gastroenterology, Kagoshima University Hospital, between May 2018 and December 2023. The median age of the cohort was 71 years, and 82.1% of the patients were male. The median blood pressure at admission was 128/73 mmHg, which significantly increased to 136/76 mmHg the day after lenvatinib administration. Grade 3 hypertension (≥160/100 mmHg) occurred in 37.3% of patients during hospitalization. The median increase in systolic blood pressure from admission to its peak during hospitalization was 26 mmHg. Patients who experienced an increase in blood pressure of ≥26 mmHg were classified into the blood pressure elevation group, which showed a significantly lower mortality rate than that of the blood pressure non-elevation group (35.3% vs. 81.8%, log-rank p = 0.007), even after adjusting for age, sex, disease stage, performance status, and liver reserve function. This study demonstrated that patients who experienced earlier blood pressure elevation after lenvatinib administration had lower overall mortality rates. These findings suggest that blood pressure elevations after lenvatinib initiation may serve as valuable prognostic indicators in patients with cancer undergoing lenvatinib therapy. | |||||
| 内容記述言語 | en | |||||
| 要約 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Keisuke Shibata, Yuichi Akasaki, Akihiro Tokushige, Mina Nitta, Shin Kawasoe, Takuro Kubozono, Kohei Oda, Kotaro Kumagai, Seiichi Mawatari & Mitsuru Ohishi Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis Hypertens Res 48, 1542–1553 (2025) https://doi.org/10.1038/s41440-025-02149-4 |
|||||
| 内容記述言語 | en | |||||
| 要約 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | The version of record of this article, first published in Hypertension Research, is available online at Publisher’s website: https://doi.org/10.1038/s41440-025-02149-4 | |||||
| 内容記述言語 | en | |||||
| 作成日 | ||||||
| 日付 | 2025-06-05 | |||||
| 日付タイプ | Collected | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| ファイル（説明） | ||||||
| 内容記述 | 博士論文全文, 博士論文要旨, 最終試験結果の要旨, 論文審査の要旨 | |||||
| 公開者・出版者 | ||||||
| 出版者 | Springer Nature | |||||
| 出版者言語 | en | |||||
| 公開者・出版者 | ||||||
| 出版者 | 鹿児島大学 | |||||
| 出版者言語 | ja | |||||
| 備考 | ||||||
| 備考言語 | ja | |||||
| 備考 | 【指導教員:大石充】 | |||||
| date.appl | ||||||
| appl | 【学位申請日】2025-04-09 | |||||
| 学位名 | ||||||
| 学位名の言語 | ja | |||||
| 学位名 | 博士(医学) | |||||
| 学位名 | ||||||
| 学位名の言語 | en | |||||
| 学位名 | Doctor of Philosophy in Medical Science | |||||
| 学位授与機関名 | ||||||
| 学位授与機関識別子Scheme | kakenhi | |||||
| 学位授与機関識別子 | 17701 | |||||
| 学位授与機関名の言語 | ja | |||||
| 学位授与機関名 | 鹿児島大学 | |||||
| 学位授与年月日 | ||||||
| 学位授与年月日 | 2025-06-12 | |||||
| 学位授与番号 | ||||||
| 学位授与番号 | 甲総研第792号 | |||||
